Open Access Gold möglich sobald Verlagsversion bei der ZB eingereicht worden ist.
Identification of autophagy as a functional target suitable for the pharmacological treatment of mitochondrial membrane protein-associated neurodegeneration (MPAN) in vitro.
Pharmaceutics 15:19 (2023)
Mitochondrial membrane protein-associated neurodegeneration (MPAN) is a relentlessly progressive neurodegenerative disorder caused by mutations in the C19orf12 gene. C19orf12 has been implicated in playing a role in lipid metabolism, mitochondrial function, and autophagy, however, the precise functions remain unknown. To identify new robust cellular targets for small compound treatments, we evaluated reported mitochondrial function alterations, cellular signaling, and autophagy in a large cohort of MPAN patients and control fibroblasts. We found no consistent alteration of mitochondrial functions or cellular signaling messengers in MPAN fibroblasts. In contrast, we found that autophagy initiation is consistently impaired in MPAN fibroblasts and show that C19orf12 expression correlates with the amount of LC3 puncta, an autophagy marker. Finally, we screened 14 different autophagy modulators to test which can restore this autophagy defect. Amongst these compounds, carbamazepine, ABT-737, LY294002, oridonin, and paroxetine could restore LC3 puncta in the MPAN fibroblasts, identifying them as novel potential therapeutic compounds to treat MPAN. In summary, our study confirms a role for C19orf12 in autophagy, proposes LC3 puncta as a functionally robust and consistent readout for testing compounds, and pinpoints potential therapeutic compounds for MPAN.
Altmetric
Weitere Metriken?
Zusatzinfos bearbeiten
[➜Einloggen]
Publikationstyp
Artikel: Journalartikel
Dokumenttyp
Wissenschaftlicher Artikel
Schlagwörter
Abt-737 ; C19orf12 ; Lc3 ; Ly294002 ; Autophagy ; Carbamazepine ; Mitochondria Membrane Protein-associated Neurodegeneration (mpan) ; Neurodegeneration With Brain Iron Accumulation (nbia) ; Oridonin ; Paroxetine; Patient
ISSN (print) / ISBN
1999-4923
e-ISSN
1999-4923
Zeitschrift
Pharmaceutics
Quellenangaben
Band: 15,
Heft: 1,
Artikelnummer: 19
Verlag
MDPI
Verlagsort
St Alban-anlage 66, Ch-4052 Basel, Switzerland
Nichtpatentliteratur
Publikationen
Begutachtungsstatus
Peer reviewed
Förderungen
NBIA Disorders Association
NBIA Poland
Euro-BioImaging Italian Fund
Hoffnungsbaum e.V.
NBIA Suisse
Million Dollar Bike Ride program
NBIA Poland
Euro-BioImaging Italian Fund
Hoffnungsbaum e.V.
NBIA Suisse
Million Dollar Bike Ride program